SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Logistics who wrote (18706)5/18/1998 10:38:00 AM
From: Leman  Read Replies (1) of 34592
 
check out ATLC as a cancer play ATLC is engaged in the development of biomedical and pharmaceutical products and technologies
for use in a variety of diseases including cancer, infection, opthalmic disorders, pain and
inflammation, cardiovascular diseases and dermatological conditions. For the fiscal year ended
12/97, revenues fell 98% to $2 thousand. Net loss applicable to Common totalled $8.9 million, up
from $3.6 million. Results reflects a decrease in grant income. Higher losses reflect increased R&D
activities.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News